Agreements reached under this partnership
Business Alliances- 1
リボミック will provide its DDS aptamer technology, and Nissan Chemical Corporation will conduct research using its proprietary nucleic acid drug discovery technology.
- 2
Nissan Chemical Corporation will apply its proprietary nucleic acid technology to リボミック’s DDS aptamer technology.
- 3
Establishment of new platform technologies for the creation of pharmaceuticals targeting central nervous system diseases
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
No consideration will arise in the fiscal year ending March 2026, and this matter will have no impact on results for the fiscal year ending March 2026.
| Item | Details |
|---|---|
| Name of alliance partner | Nissan Chemical Corporation |
| Alliance partner's business activities | Functional Materials, Agricultural Chemicals, Chemicals, and Healthcare |
| Alliance partner's location | Chuo-ku, Tokyo |
| Alliance partner's capital | ¥18,942 million |
| Alliance partner's net sales | ¥251,365 million (fiscal year ended March 2025) |
| Alliance partner's operating income | ¥56,833 million (fiscal year ended March 2025) |
| Type of alliance | Business Alliances |
| Details of the alliance | リボミック will provide its DDS aptamer technology, and Nissan Chemical Corporation will conduct research using its proprietary nucleic acid drug discovery technology., Nissan Chemical Corporation will apply its proprietary nucleic acid technology to リボミック’s DDS aptamer technology., Establishment of new platform technologies for the creation of pharmaceuticals targeting central nervous system diseases |
| Date of board resolution | 26 March 2026 |
| Contract Date | 26 March 2026 |
| Alliance start date | 1 April 2026 |
| Impact on Business Performance | No consideration will arise in the fiscal year ending March 2026, and this matter will have no impact on results for the fiscal year ending March 2026. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To combine the two companies’ technological strengths, advance research and development in the central nervous system disease field based on Nissan Chemical Corporation’s nucleic acid drug discovery technology, and lead to further joint research and applications in the future.